drugset / Trial / NCT06126237
A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multi-center, open-label, Phase 1/2 study to evaluate the safety, tolerability, Pharmacokinetics, pharmacodynamics and Preliminary Efficacy of CM313 in Subjects with Relapsed or Refractory Multiple Myeloma.
Timeline
- Start
- 2024-02-28
- Primary completion
- 2026-02-28
- Completion
- 2026-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LUMROTATUG | Monoclonal antibody | — | Subcutaneous |